<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1755</journal-id><journal-id journal-id-type="pmc-domain">frontonco</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12757875</article-id><article-id pub-id-type="pmcid-ver">PMC12757875.1</article-id><article-id pub-id-type="pmcaid">12757875</article-id><article-id pub-id-type="pmcaiid">12757875</article-id><article-id pub-id-type="pmid">41487593</article-id><article-id pub-id-type="doi">10.3389/fonc.2025.1680921</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The DDR-immune fitness score: a biomarker for guiding parp and immunotherapy synergy in extensive-stage small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yinxu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xiaoyang</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="D">Dai</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="X">Xuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuxi</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="G">Guangyu</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xiaomei</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/937757/overview"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Surgery, The First Affiliated Hospital of Jinzhou Medical University</institution>, <city>Jinzhou</city>, <state>Liaoning</state>,&#160;<country country="cn">China</country></aff><aff id="aff2"><label>2</label><institution>Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University</institution>, <city>Jinzhou</city>, <state>Liaoning</state>,&#160;<country country="cn">China</country></aff><aff id="aff3"><label>3</label><institution>Department of Anesthesiology, Medical College of Jinzhou Medical University</institution>, <city>Jinzhou</city>, <state>Liaoning</state>,&#160;<country country="cn">China</country></aff><author-notes><corresp id="c001"><label>*</label>Correspondence: Xiaomei Liu, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:liuxm@jzmu.edu.cn">liuxm@jzmu.edu.cn</email></corresp><fn fn-type="other" id="fn003"><label>&#8224;</label><p>These authors share first authorship</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-12-19"><day>19</day><month>12</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">480898</issue-id><elocation-id>1680921</elocation-id><history><date date-type="received"><day>06</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>12</month><year>2025</year></date><date date-type="rev-recd"><day>03</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-05 09:25:15.180"><day>05</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Zhang, Chen, Wang, Zhou, Wang, Zhang and Liu.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang, Chen, Wang, Zhou, Wang, Zhang and Liu</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-12-18">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fonc-15-1680921.pdf"/><abstract><sec><title>Background</title><p>Despite the integration of PD-L1 inhibitors with chemotherapy, extensive-stage small-cell lung cancer (ES-SCLC) continues to portend a dismal prognosis, with a 5-year survival rate below 10%. A critical unmet need is the lack of validated biomarkers to identify patients who may benefit from novel combinations of DNA damage repair (DDR) inhibitors and immune checkpoint blockers (ICB).</p></sec><sec><title>Methods</title><p>We developed a novel three-variable biomarker, the DDR-Immune Fitness (DDR-IF) score, by integrating data from a systematic review of six phase II trials (PRISMA-2020) with single-cell transcriptomic data from 82 SCLC tumors. The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity. Its predictive performance was validated in an independent cohort from the MSK-IMPACT study (n=152 ES-SCLC patients receiving PARP-ICB).</p></sec><sec><title>Results</title><p>DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p &lt; 0.001), (ii) significantly reduced CD8<sup>+</sup> T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% <italic toggle="yes">vs</italic> 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).</p></sec><sec><title>Conclusion</title><p>The DDR-IF score unifies measures of genomic instability and immune contexture to identify a therapeutically vulnerable subset of ES-SCLC patients most likely to benefit from PARP-ICB synergy. It represents a promising, though exploratory, framework for personalizing immunotherapy in ES-SCLC, whose clinical utility requires confirmation in prospective multicenter trials.</p></sec></abstract><kwd-group><kwd>DNA damage repair pathway (DDR)</kwd><kwd>immune checkpoint blockade</kwd><kwd>small cell lung cancer (SCLC)</kwd><kwd>synthetic lethality</kwd><kwd>targeted therapy</kwd><kwd>tumor microenvironment</kwd></kwd-group><funding-group><funding-statement>The author(s) declared financial support was received for this work and/or its publication. This project was supported by funds from the Wu Jieping Medical Foundation (Grant No: 320.6750.2025-6-21).</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="0"/><equation-count count="0"/><ref-count count="82"/><page-count count="14"/><word-count count="6159"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cancer Molecular Targets and Therapeutics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><label>1</label><title>Background</title><p>Extensive-stage small cell lung cancer (ES-SCLC) presents a critical unmet need in oncology (<xref rid="B1" ref-type="bibr">1</xref>). Although over 70% of cases harbor potentially actionable DNA damage repair (DDR) defects (COSMIC v99), a validated biomarker to identify patients most likely to benefit from combinations of DDR inhibitors and immune checkpoint blockers (DDR-ICB) remains elusive (<xref rid="B1" ref-type="bibr">1</xref>). Current biomarker research in ES-SCLC is fragmented, often relying on single-parameter approaches that fail to capture the complex interplay between genomic instability and the immune microenvironment (<xref rid="B2" ref-type="bibr">2</xref>). To address this gap, we developed the DDR-Immune Fitness (DDR-IF) score-a composite biomarker that integrates measures of genomic instability (homologous recombination deficiency [HRD] and tumor mutational burden [TMB]) with immune contexture (STING pathway activation), derived from single-cell multi-omics data of 82 SCLC tumors (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>).</p><p>This review is structured to build a comprehensive translational case for the DDR-IF score, which serves as the central focus of our article. We first establish the biological rationale by detailing the specific mechanisms of DDR-immune crosstalk in SCLC that directly inform the score&#8217;s components (Sections 2 &amp; 3). We then describe the empirical construction and validation of the DDR-IF score itself (Section 4), and finally discuss its therapeutic implications and future directions within a precision oncology framework.</p><p>The DDR-IF score is the first SCLC-specific tool designed to prospectively stratify patients for DDR-ICB therapy. While existing biomarkers such as SLFN11 expression or ATM mutation status show some association with PARP inhibitor (PARPi) response, their predictive power is limited, as they primarily reflect intrinsic tumor cell vulnerability without fully accounting for the immune landscape required for ICB synergy (<xref rid="B4" ref-type="bibr">4</xref>). The DDR-IF score addresses this limitation by integrating multi-dimensional features to improve predictive accuracy (<xref rid="B4" ref-type="bibr">4</xref>). Derived from an analysis of 82 SCLC single-cell transcriptomes and six phase II trials, it robustly identifies DDR-IF-high tumors, which are characterized by cGAS-STING pathway exhaustion, reduced CD8<sup>+</sup> TIL infiltration, and a superior pooled objective response rate (ORR) to PARP-ICB combinations (42% <italic toggle="yes">vs</italic>. 18%) (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Mechanistically, DDR abnormalities in SCLC drive immune evasion through pathways including cGAS-STING exhaustion, PD-L1 upregulation, and metabolic reprogramming (<xref rid="B7" ref-type="bibr">7</xref>). Consequently, therapeutic strategies that concurrently target DDR proteins (e.g., RAD51, PARP) and immune checkpoints hold significant promise (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Although validation of the DDR-IF score is ongoing in prospective clinical studies, and limitations such as ethnic variability and technical discrepancies in STING quantification require further addressing, the DDR-IF framework represents a pivotal, though exploratory, step toward precision guidance for DNA damage response-immune checkpoint blockade (DDR-ICB) therapy in ES-SCLC, requiring rigorous prospective validation.</p></sec><sec id="s2"><label>2</label><title>Current status of SCLC and the basics of the DDR pathway</title><p>DDR pathway abnormalities are a hallmark of SCLC, contributing not only to genomic instability but also to extensive remodeling of the tumor microenvironment (TME) (<xref rid="B10" ref-type="bibr">10</xref>). Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%) (<xref rid="B11" ref-type="bibr">11</xref>). This high prevalence underscores the therapeutic potential of targeting DDR pathways in this disease.</p><p>The interplay between DDR deficiency and the immune TME is complex and central to the rationale of the DDR-IF score (<xref rid="B12" ref-type="bibr">12</xref>). As schematically illustrated in <xref rid="f1" ref-type="fig"><bold>Figure&#160;1</bold></xref>, DDR pathway abnormalities initially trigger cGAS-STING signaling. However, in the context of sustained DDR dysfunction, this leads to a state of cGAS-STING pathway exhaustion, which subsequently upregulates PD-L1 expression and impairs T-cell function. This cascade forms a feedforward loop that reinforces a profoundly immunosuppressive TME (<xref rid="B13" ref-type="bibr">13</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Schematic of DDR pathway-immune crosstalk and therapeutic responses in SCLC. Cisplatin induces double-strand breaks (DSBs) that remain unrepaired in homologous recombination (HR)-deficient tumor cells, causing DNA repair failure. DDR inhibitors (PARP inhibitors, RAD51 inhibitors) block base excision repair (BER) or HR, further accumulating single-strand breaks (SSBs) and DSBs. This triggers reactive oxygen species (ROS) release, altered MHC-I expression, and PD-L1 upregulation&#8212;all of which, alongside glycolysis-derived lactic acid, suppress T cell activation and infiltration in the tumor microenvironment (TME). Monotherapy (DDR inhibitors or PD-L1 antibodies alone) has limited efficacy, while combination therapy (DDR inhibitors + PD-L1 antibodies) restores dendritic cell (DC) MHC-II/CD86 expression, enhances CD8<sup>+</sup> cytotoxic T cell infiltration, and reverses immune suppression to induce tumor apoptosis. This mechanism supports the DDR-IF score&#8217;s role in guiding PARP-ICB therapy for SCLC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-15-1680921-g001.jpg"><alt-text content-type="machine-generated">Diagram showing a pathway where DNA damage in DDR defective tumors activates the cGAS-STING pathway, leading to DNA-driven immune responses. This causes CD8+ T cell exclusion. The presence of PD-L1 inhibits immune response, but combining RAD51i with anti-PD-L1 treatment results in tumor regression.</alt-text></graphic></fig><p>It is this specific biological interplay-where profound DDR defects create an &#8220;immunologically cold&#8221; yet therapeutically targetable niche-that the DDR-IF score is designed to capture. The score directly addresses the urgent need for a composite biomarker that integrates genomic (HRD, TMB) and immune (STING activation) dimensions (<xref rid="B14" ref-type="bibr">14</xref>). By doing so, it provides a mechanistic explanation for why DDR-IF-high tumors, characterized by these coordinated defects, show heightened susceptibility to PARP-ICB combination therapy, which simultaneously targets DNA repair and immune checkpoint pathways (<xref rid="B14" ref-type="bibr">14</xref>).</p></sec><sec id="s3"><label>3</label><title>Methods: derivation and validation of the DDR-IF score</title><sec id="s3_1"><label>3.1</label><title>Systematic review and data integration</title><p>A systematic literature search was conducted following PRISMA-2020 guidelines across PubMed, Embase, Cochrane Library, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> from inception to April 2024. The search strategy used a combination of keywords and MeSH terms related to &#8220;small cell lung cancer,&#8221; &#8220;PARP inhibitor,&#8221; &#8220;immunotherapy,&#8221; and &#8220;clinical trial.&#8221; The predefined inclusion criteria were: (1) phase II clinical trials; (2) enrolled patients with extensive-stage (ES) SCLC; (3) evaluated combination therapy of a PARP inhibitor and an immune checkpoint blocker; (4) reported objective response rate (ORR) data. After duplicate removal, title/abstract screening, and full-text review, six trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02484404">NCT02484404</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02734004">NCT02734004</ext-link>, etc.) fulfilled all criteria and were included for pooled outcome analysis (see PRISMA flow diagram, <xref rid="SF2" ref-type="supplementary-material"><bold>Supplementary Figure S1</bold></xref>). To derive the biomarker, we integrated single-cell RNA sequencing (scRNA-seq) data from 82 treatment-na&#239;ve SCLC tumors from a public repository (e.g., GEO: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE187285">GSE187285</ext-link>).</p></sec><sec id="s3_2"><label>3.2</label><title>Data-access statement for included trials</title><p>All six phase-II trials are publicly registered. Readers can access detailed protocols, inclusion/exclusion criteria and results at the following portals (last accessed 15 Nov 2025):</p><list list-type="simple"><list-item><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02484404">NCT02484404</ext-link>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02484404" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02484404</ext-link>.</p></list-item><list-item><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02734004">NCT02734004</ext-link>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02734004" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02734004</ext-link>.</p></list-item><list-item><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03041311">NCT03041311</ext-link>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03041311" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03041311</ext-link>.</p></list-item><list-item><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03401385">NCT03401385</ext-link>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03401385" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03401385</ext-link>.</p></list-item><list-item><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03517449">NCT03517449</ext-link>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03517449" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03517449</ext-link>.</p></list-item><list-item><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04039568">NCT04039568</ext-link>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04039568" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04039568</ext-link>.</p></list-item></list><p>For each trial, patient-level ORR, PFS and biomarker data were extracted from published manuscripts or supplementary tables; no proprietary datasets were requested.</p></sec><sec id="s3_3"><label>3.3</label><title>Biomarker construction</title><p>From the scRNA-seq data, we computed three core metrics for each tumor: 1) Homologous Recombination Deficiency (HRD) score using the scarHRD algorithm; 2) Tumor Mutational Burden (TMB) from matched whole-exome sequencing; and 3) STING Pathway Activation score using Gene Set Variation Analysis (GSVA) with a curated gene signature (see <xref rid="SF1" ref-type="supplementary-material"><bold>Supplementary Methods</bold></xref>). An elastic net regression model (&#945;=0.5, &#955;=0.05 determined via 10-fold cross-validation) was trained on the integrated cohort (n=82 tumors) to predict binarized response (Responder <italic toggle="yes">vs</italic>. Non-responder). The final DDR-IF score was defined using standardized coefficients: DDR-IF = 0.4 &#215; (HRD score) + 0.35 &#215; log<sub>10</sub>(TMB + 1) + 0.25 &#215; (STING activation score), where all predictors were z-score normalized prior to model fitting.</p></sec><sec id="s3_4"><label>3.4</label><title>Elastic-net regression details</title><p>We used the glmnet package (v4.1-7) in R 4.3.0. Prior to model fitting, continuous variables (HRD, log10(TMB + 1), STING activation) were scaled to unit variance and zero mean; binary response (objective response <italic toggle="yes">vs</italic>. non-response) was used as the dependent variable. The regularization path was constructed with 100 &#955; values; optimal &#955; (0.05) was selected by 10-fold cross-validation with misclassification error as the criterion, giving &#945;=0.5. Single-cell input: for each of the 82 treatment-na&#239;ve SCLC tumours, gene-level UMI counts were log2-normalised (pseudocount = 1); HRD was calculated with scarHRD v1.1, TMB with maftools v2.14.0, and STING pathway activation with GSVA v1.46.0 using the curated 17-gene STING signature (TBK1, IRF3, IFNB1, CCL5, CXCL10, etc.). All three metrics were averaged across malignant cells (&#8805;500 cells per tumor) to obtain tumor-level values for regression.</p></sec><sec id="s3_5"><label>3.5</label><title>Validation and cut-off determination</title><p>Model performance was assessed using the Area Under the Receiver Operating Characteristic Curve (AUROC). A cut-off value of &#8805;0.65 for defining &#8220;DDR-IF-high&#8221; status was determined by maximizing Youden&#8217;s index in the training cohort. This model was then applied to an independent validation cohort from the MSK-IMPACT study (n=152 ES-SCLC patients receiving PARP-ICB regimens).</p></sec><sec id="s3_6"><label>3.6</label><title>Limitations of the derivation approach</title><p>It is crucial to note that the derivation cohort is limited in size (n=82) and retrospective. The integration of response data from separate trials introduces potential heterogeneity. These factors increase the risk of overfitting and necessitate that the DDR-IF score be considered exploratory, requiring prospective validation in dedicated, multi-center trials before clinical application.</p></sec><sec id="s3_7"><label>3.7</label><title>Tumor purity and non-DDR mutations</title><p>We estimated tumor-cell fraction with ESTIMATE v2.0 for each scRNA-seq library; median purity was 0.68 (IQR 0.59-0.76). HRD and TMB values were recalculated after excluding genes with &lt;10&#215; coverage or &lt;30% malignant-cell expression, ensuring that stromal/immune reads do not inflate genomic instability metrics. To test whether non-DDR mutations confound the DDR-IF score, we included 1,000 randomly selected non-DDR somatic mutations as an additional &#8220;background TMB&#8221; variable in the elastic-net model; its coefficient was shrunk to zero in 997 of 1,000 bootstrap iterations, confirming that the score is driven by DDR-related features and not by overall mutation load.</p></sec></sec><sec id="s4"><label>4</label><title>Abnormal DDR pathway in SCLC</title><sec id="s4_1"><label>4.1</label><title>High-impact somatic DDR alterations</title><p>The prevalence of high-impact somatic DDR alterations in SCLC provides the foundational rationale for the HRD component of the DDR-IF score (<xref rid="B15" ref-type="bibr">15</xref>). For instance, mutations in BRCA1/2 and PARP1 amplification correlate with genomic instability, which is directly quantified by the HRD metric (<xref rid="B16" ref-type="bibr">16</xref>). A meta-analysis of six trials (2020&#8211;2024) confirmed that DDR-IF-high tumors (e.g., ATM/BRCA1/2-altered) show a 2.3-fold higher ORR to PARP-ICB versus DDR-IF-low (42% <italic toggle="yes">vs</italic>. 18%, p=0.003) (<xref rid="B17" ref-type="bibr">17</xref>). While promising, this analysis has limitations, including cohort heterogeneity and a constrained sample size (n=82) that increases overfitting risk. Although internally validated, these limitations underscore the necessity for prospective, multi-center validation.</p><p>The interplay between DDR deficiency and the tumor immune microenvironment (TME) is complex (<xref rid="B18" ref-type="bibr">18</xref>). Generally, DDR mutations are enriched in interferon-&#8221;desert&#8221; TME clusters, correlating with suppressed immunity and diminished immunotherapy response (<xref rid="B19" ref-type="bibr">19</xref>). However, not all DDR defects confer resistance; for example, MSH2 mutations (n=5/82) trended towards higher CD8<sup>+</sup> TILs (p=0.08), likely due to increased neoantigen burden, highlighting the nuanced role of specific pathways (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>To quantitatively validate the comparative advantage of our composite score, we performed a head-to-head analysis against established biomarkers. In our cohort, the DDR-IF score demonstrated superior predictive power for PARP-ICB response (AUROC = 0.81) compared to SLFN11 expression alone (AUROC = 0.64), ATM mutation status (AUROC = 0.59), or a simple TMB-PD-L1 composite model (AUROC = 0.72). This underscores the limitation of single-feature biomarkers that capture intrinsic tumor vulnerability but fail to integrate the immune contexture essential for predicting ICB synergy (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>).</p><p>These findings collectively demonstrate that a composite biomarker is essential (<xref rid="B22" ref-type="bibr">22</xref>). The DDR-IF score, which integrates specific DDR alterations (contributing to the HRD component) with key TME features, represents such a tool (<xref rid="B23" ref-type="bibr">23</xref>). This integrated approach overcomes the limitations of single-gene biomarkers (e.g., SLFN11, ATM), which, while predictive for PARPi monotherapy, often fail to capture the immune contexture required for predicting ICB synergy.</p></sec><sec id="s4_2"><label>4.2</label><title>Proteomic landscape of DDR over-activation</title><p>Quantitative proteomics (n=12 SCLC lines) ranks SCLC highest for PARP1 abundance (median iBAQ 12.4; IQR 10.1-14.7; p&lt;0.01 <italic toggle="yes">vs</italic>. TNBC) (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). PARP1 overactivity confers cisplatin resistance and mechanistically acts as an E2F1 co-activator to enhance PD-L1 transcription, as validated by CUT&amp;RUN in H446 cells (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>Increased RAD51 staining is associated with decreased CD8<sup>+</sup> TIL infiltration, suggesting homologous recombination may inhibit immune cell recruitment (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Multiplex-IF (n=82) demonstrated that PARP1-high tumors (H-score &#8805;150) exhibited 2.3-fold fewer CD8<sup>+</sup> TILs (p=0.004) and diminished p-STING (&lt;5% area), indicating immune-cold phenotypes (<xref rid="B28" ref-type="bibr">28</xref>)(<xref rid="f2" ref-type="fig"><bold>Figure&#160;2</bold></xref>). <xref rid="f2" ref-type="fig"><bold>Figure&#160;2</bold></xref> delineates how DDR abnormalities at genomic, proteomic, and pathway levels converge to suppress anti-tumor immunity. The reduced p-STING in PARP1-high tumors directly links DDR over-activation to STING pathway exhaustion, supporting its inclusion in the DDR-IF score (<xref rid="B29" ref-type="bibr">29</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Schematic of multi-level (genetic, proteomic, pathway) DDR abnormalities driving immune suppression in SCLC. Genetic defects (e.g., ATM, BRCA mutations; MMR deficiency) and dysregulated factors (P53, TGF-&#946;) trigger DDR dysfunction, leading to mitochondrial DNA release and cytosolic DNA accumulation. This initially activates the cGAS-STING pathway to produce IFN-&#946;, but continuous exposure induces pathway exhaustion. Concurrently, DDR abnormalities drive glycolysis dysfunction, increasing lactic acid and ROS production, which suppress MHC-I expression and antigen presentation by dendritic cells (DCs). Upregulated PD-L1, IL-10, and Treg recruitment (via Foxp3/STAT1) further inhibit naive T cell activation and proliferation, while MDSCs exacerbate immune suppression. These convergent mechanisms shape an &#8220;immunologically cold&#8221; TME, supporting the inclusion of STING pathway activity in the DDR-IF score to identify tumors susceptible to PARP-ICB therapy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-15-1680921-g002.jpg"><alt-text content-type="machine-generated">Diagram comparing monotherapy and combination therapy in cancer treatment. Monotherapy involves RAD51 and PARP inhibition with DNA repair failure leading to apoptosis. Combination therapy illustrates enhanced immune response through DDR inhibition, cocyclosis, and T cell activation. Components include PD-L1 antibodies, MHC molecules, ROS, CD8+ cytotoxic T cells, and dendritic cells. Arrows indicate processes like T cell activation and infiltration.</alt-text></graphic></fig></sec><sec id="s4_3"><label>4.3</label><title>Dysregulated DDR-immune crosstalk</title><p>In SCLC, aberrant DDR-immune interactions drive immune evasion (<xref rid="B30" ref-type="bibr">30</xref>). Impaired cell-cycle checkpoints (e.g., via p21 downregulation) allow unchecked proliferation despite DNA damage, propagating genomic instability (<xref rid="B31" ref-type="bibr">31</xref>).</p><p>Single-cell trajectory analysis reveals that cells with dysregulated checkpoints accumulate micronuclei, triggering chronic, sub-threshold cGAS-STING activation (<xref rid="B32" ref-type="bibr">32</xref>). This state, termed &#8216;cGAS-STING pathway exhaustion&#8217;, is defined as an acquired, functional insensitivity of the pathway characterized by diminished STING protein phosphorylation and a failure to produce downstream type I interferons and chemokines, despite the presence of cytosolic DNA (<xref rid="B33" ref-type="bibr">33</xref>). It is mechanistically and functionally distinct from the adaptive immune dysfunction of T-cell exhaustion (<xref rid="B33" ref-type="bibr">33</xref>). This results in a profoundly interferon-desert TME with scant CD8<sup>+</sup> T cell infiltration, effectively creating an &#8216;immunologically cold&#8217; tumor (<xref rid="B34" ref-type="bibr">34</xref>). Our findings clarify a central paradox: why SCLC tumors with high genomic instability (a source of neoantigens) can remain refractory to ICB monotherapy-they lack the functional innate immune sensing apparatus necessary to initiate an adaptive anti-tumor response. This creates a profoundly interferon-desert TME, solidifying an &#8216;immunologically cold&#8217; phenotype (<xref rid="B35" ref-type="bibr">35</xref>). The STING activation component of the DDR-IF score quantifies this exhaustion, identifying tumors with crippled innate immune sensing-a hallmark of the DDR-IF-high subgroup susceptible to combination therapies (e.g., PARPi + anti-PD-L1) that aim to reverse this state (<xref rid="B36" ref-type="bibr">36</xref>).</p></sec></sec><sec id="s5"><label>5</label><title>The mechanistic basis for DDR-immune integration: informing the DDR-IF score</title><p>The DDR-IF score is grounded in the multifaceted crosstalk between genomic instability and the immune microenvironment (<xref rid="B37" ref-type="bibr">37</xref>). DDR pathway abnormalities not only affect genomic stability but also substantially impact the TME, suppressing immune responses and promoting evasion (<xref rid="B38" ref-type="bibr">38</xref>). The integration of HRD, TMB, and STING activation into a single score is necessitated by the following key immunosuppressive mechanisms:</p><sec id="s5_1"><label>5.1</label><title>Mechanistic basis of the DDR-IF score: multifaceted DDR-driven immunosuppression</title><p>DDR abnormalities sculpt an immunosuppressive TME through several mechanisms: (i) Impaired Antigen Presentation: ATM mutations blunt DNA repair, leading to reduced MHC-I synthesis and impaired T-cell recognition (<xref rid="B39" ref-type="bibr">39</xref>). (ii) Immune Checkpoint Upregulation: DDR deficiencies, including ATM loss, are associated with upregulated PD-L1, facilitating immune evasion (<xref rid="B40" ref-type="bibr">40</xref>). (iii) Metabolic Reprogramming: DDR-dysregulated cells exhibit a heightened Warburg effect, increasing lactate production that inhibits immune cell function and polarizes macrophages toward a pro-tumor M2 phenotype (<xref rid="B41" ref-type="bibr">41</xref>). These mechanisms, illustrated in <xref rid="f3" ref-type="fig"><bold>Figure&#160;3</bold></xref>, explain why single-dimensional biomarkers (e.g., PD-L1 alone) fail to stratify SCLC patients adequately.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Schematic of the interactive inhibitory crosstalk between DDR pathway abnormalities and the tumor immune microenvironment (TME) in SCLC. DDR-defective tumors accumulate DNA damage, which initially activates the cGAS-STING pathway-triggering IRF3/NF-&#954;B/IRF7 signaling, type I interferon (IFN) production, and a DNA-driven immune response. However, sustained DDR dysfunction leads to cGAS-STING exhaustion and PD-L1 upregulation, resulting in CD8<sup>+</sup> T cell exclusion and impaired anti-tumor immunity. Targeting DDR (e.g., RAD51 inhibitors) combined with anti-PD-L1 blockade reverses this inhibitory loop: DDR inhibition enhances genomic instability and immune activation, while anti-PD-L1 restores CD8<sup>+</sup> T cell function, ultimately driving tumor regression. This interplay underscores the mechanistic basis for DDR-ICB synergy, which the DDR-IF score is designed to predict.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-15-1680921-g003.jpg"><alt-text content-type="machine-generated">Scientific diagram illustrating cellular pathways involving DNA damage response (DDR) and immune system interactions. It shows how various proteins like P53, ATM, and ROS influence mitochondrial function, glycolysis, and inflammatory responses. Components such as CGAS, CGAMP, and STING are part of the signaling cascade. Tregs, na&#239;ve T cells, and DC cells are depicted, highlighting interactions like antigen recognition, T cell activation, and immune inhibition. Multiple sub-cellular structures and reactions are interlinked, emphasizing the complex network of molecular communications within cells and the immune system.</alt-text></graphic></fig></sec><sec id="s5_2"><label>5.2</label><title>DDR pathway abnormalities and up-regulation of immune checkpoints</title><p>In SCLC, DDR perturbations specifically elevate PD-L1 expression compared to other cancers (<xref rid="B41" ref-type="bibr">41</xref>). For example, ATM mutations are associated with PD-L1 upregulation, inhibiting T-cell activity (<xref rid="B40" ref-type="bibr">40</xref>). Beyond PD-L1, DDR blockade upregulates other checkpoints like TIGIT ligands (CD155) and LAG-3, suggesting avenues for multi-checkpoint co-targeting (<xref rid="B42" ref-type="bibr">42</xref>).</p></sec><sec id="s5_3"><label>5.3</label><title>Modulation of immune cell infiltration and function by DDR pathways</title><p>Beyond directly inducing checkpoint expression, DDR pathway activities exert profound effects on immune cell composition and function within the TME (<xref rid="B43" ref-type="bibr">43</xref>). Inhibiting key DDR proteins can paradoxically enhance anti-tumor immunity by altering the immune landscape (<xref rid="B43" ref-type="bibr">43</xref>). For instance, RAD51 inhibition significantly increased the CD8<sup>+</sup>/Treg ratio in patient-derived SCLC organoids (flow cytometry, n=5, p = 0.004) (<xref rid="B44" ref-type="bibr">44</xref>). Similarly, suppression of PARP or CHK1 has been shown to promote the infiltration of cytotoxic T lymphocytes (CTLs) in SCLC models (<xref rid="B45" ref-type="bibr">45</xref>). Furthermore, ATM inhibition can hinder Treg-mediated senescence of CD8<sup>+</sup> T cells, potentially preserving their cytotoxic capacity (<xref rid="B46" ref-type="bibr">46</xref>). These findings illustrate that targeting DDR nodes can actively remodel the immunosuppressive TME, providing a mechanistic basis for the synergy observed in DDR-ICB combinations (<xref rid="B30" ref-type="bibr">30</xref>).</p></sec><sec id="s5_4"><label>5.4</label><title>Metabolic reprogramming as a mechanism of DDR-mediated immunosuppression</title><p>DDR dysregulation is intricately linked to metabolic rewiring in SCLC, which constitutes another layer of immune suppression (<xref rid="B47" ref-type="bibr">47</xref>). SCLC cells with DDR pathway abnormalities often exhibit a heightened glycolytic phenotype, known as the Warburg effect, even under normoxic conditions (<xref rid="B48" ref-type="bibr">48</xref>). This metabolic shift has direct immunosuppressive consequences (<xref rid="B48" ref-type="bibr">48</xref>). Stable isotope tracing (U-&#185;&#179;C-glucose, n=3) demonstrated that RAD51 inhibition increased intratumoral lactate production by 2.1-fold, which in turn polarized tumor-associated macrophages (TAMs) toward an M2-like, pro-tumor phenotype (CD206<sup>+</sup>, p = 0.02) (<xref rid="B49" ref-type="bibr">49</xref>). The accumulation of lactate in the TME impairs the function of effector immune cells, including T cells and NK cells, and reinforces the immunosuppressive niche by promoting the differentiation of M2-like TAMs (<xref rid="B50" ref-type="bibr">50</xref>). This DDR-driven metabolic axis establishes a feed-forward loop that sustains an immune-resistant microenvironment (<xref rid="B50" ref-type="bibr">50</xref>).</p></sec><sec id="s5_5"><label>5.5</label><title>Emerging DDR-linked immune checkpoints and therapeutic nodes</title><p>The immunosuppressive landscape shaped by DDR defects extends beyond the well-characterized PD-L1 axis (<xref rid="B51" ref-type="bibr">51</xref>). Emerging evidence reveals novel DDR-immune checkpoints that represent promising therapeutic targets (<xref rid="B52" ref-type="bibr">52</xref>). For example, blockade of the ATR-CHK1 pathway leads to nuclear accumulation of the transcription factor E2F1, subsequently upregulating the immune checkpoint VSIG4 on tumor cells and the Treg chemokine receptor CCR8 (<xref rid="B53" ref-type="bibr">53</xref>). Concurrently, PARP1-mediated poly(ADP-ribosyl)ation (PARylation) of scaffold proteins recruits TAO kinase 3, which phosphorylates and stabilizes the TIGIT ligands CD155 and CD112 (<xref rid="B54" ref-type="bibr">54</xref>). In patient-derived SCLC organoids, a combination strategy employing dual TIGIT/VSIG4 blockade alongside the ATR inhibitor AZD6738 tripled the intratumoral CD8<sup>+</sup> T cell/Treg ratio (n=5; p=0.004), highlighting the potential of co-targeting these nodes (<xref rid="B55" ref-type="bibr">55</xref>).</p><p>Notably, the metabolic consequences of DDR dysfunction also interface directly with immune checkpoint biology (<xref rid="B56" ref-type="bibr">56</xref>). As noted in section 4.4, RAD51-driven Warburg effect elevates extracellular lactate (<xref rid="B50" ref-type="bibr">50</xref>). This lactate engages the receptor GPR81 on Tregs, stabilizing PD-1 expression and promoting CCR8-mediated chemotaxis, thereby further blunting anti-tumor immunity (<xref rid="B50" ref-type="bibr">50</xref>). This lactate-mediated immunosuppression can be reversed by inhibiting the lactate transporter MCT4, revealing another actionable node within the DDR-immune-metabolic network (<xref rid="B50" ref-type="bibr">50</xref>).</p></sec></sec><sec id="s6"><label>6</label><title>Therapeutic interception and the DDR-IF framework</title><p>The conceptual basis for using the DDR-IF score to stratify ES-SCLC patients and guide therapeutic selection is visualized in <xref rid="f4" ref-type="fig"><bold>Figure&#160;4</bold></xref>. This schematic integrates the three core biological dimensions of the score&#8212;HRD, TMB, and STING pathway activity&#8212;to distinguish between therapeutically vulnerable (DDR-IF-High) and resistant (DDR-IF-Low) subtypes, directly aligning with the therapeutic interception goals of this framework.</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>Schematic of the DDR-Immune Fitness (DDR-IF) Score Integration Module for ES-SCLC Patient Stratification and Therapeutic Guidance. The DDR-IF score is a composite biomarker generated via elastic-net regression, integrating three core biological dimensions with optimized weights: Homologous Recombination Deficiency (HRD, weight=0.4), log<sub>10</sub>-transformed Tumor Mutational Burden (log<sub>10</sub>(TMB + 1), weight=0.35), and STING pathway activity (weight=0.25). A cut-off value of &#8805;0.65 defines the DDR-IF-high subtype, characterized by high HRD, elevated TMB (2&#8211;3 fold higher than the low subtype), cGAS-STING pathway exhaustion, and an &#8220;immunologically cold&#8221; tumor microenvironment (TME) with 2.3-fold reduced CD8<sup>+</sup> T cell infiltration. This subtype exhibits susceptibility to synthetic lethality and potential for immune reactivation, leading to a 42% objective response rate (ORR) to PARP inhibitor-immune checkpoint blocker (PARP-ICB) combination therapy as validated in the MSK-IMPACT cohort. In contrast, the DDR-IF-low subtype (score &lt;0.65) features low HRD, modest TMB, intact homologous recombination/DNA repair function, and a functionally active STING pathway that supports an &#8220;immunologically active&#8221; TME with preserved interferon (IFN) production. Lacking drivers for PARP inhibitor synthetic lethality, this subtype shows only an 18% ORR to PARP-ICB and is recommended for standard therapy (platinum-etoposide + atezolizumab). The module enables clinical translation through tumor multi-omic profiling and DDR-IF score calculation, guiding precision therapy decisions to prioritize PARP-ICB for DDR-IF-high patients, avoid ineffective treatments for DDR-IF-low patients, reduce treatment failure risk, optimize resource allocation, and bridge the gap between genomic and immune phenotypes in ES-SCLC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-15-1680921-g004.jpg"><alt-text content-type="machine-generated">Diagram illustrating the DDR-IF Score Integration Module, which combines HRD, TMB, and STING activity to stratify ES-SCLC patients. It differentiates between DDR-IF-High (therapeutically vulnerable) with high HRD and TMB, and DDR-IF-Low (therapeutically resistant) with low HRD and modest TMB. It advises PARP-ICB therapy for DDR-IF-High and standard chemotherapy for DDR-IF-Low. Clinical translation focuses on precision therapy decisions using multi-omic profiling and therapy optimization.</alt-text></graphic></fig><sec id="s6_1"><label>6.1</label><title>Targeting DDR proteins: from preclinical promise to clinical synergy</title><p>Therapeutic targeting of key DDR proteins demonstrates significant potential for SCLC (<xref rid="B45" ref-type="bibr">45</xref>). Beyond PARP inhibitors, emerging agents like RAD51 inhibitors show remarkable promise (<xref rid="B57" ref-type="bibr">57</xref>). In the SCLC-specific phase Ib trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04564027">NCT04564027</ext-link>, the RAD51 inhibitor CYT-0851 achieved a 38% disease control rate, with matched biopsies revealing a STING-dependent 6.8-fold increase in CXCL10 (p=0.02), directly linking DDR inhibition to immune activation (<xref rid="B58" ref-type="bibr">58</xref>). Likewise, the RNA polymerase II inhibitor lurbinectedin has been shown to trigger DNA damage and potentiate PD-L1 blockade by activating the STING-IFN signaling axis in SCLC models, providing further mechanistic support for DDR-ICB synergy (<xref rid="B59" ref-type="bibr">59</xref>). Similarly, PARP inhibitors (e.g., talazoparib, niraparib) not only induce synthetic lethality but also remodel the tumor microenvironment (<xref rid="B60" ref-type="bibr">60</xref>). Combining niraparib with radiotherapy activates the cGAS/STING pathway and increases PD-L1 expression; the addition of anti-PD-1 antibodies further enhances CD3<sup>+</sup> T-cell infiltration and reduces T-cell exhaustion (<xref rid="B61" ref-type="bibr">61</xref>). These findings underscore the dual mechanism of DDR inhibitors: directly compromising tumor cell genomic integrity and indirectly stimulating anti-tumor immunity (<xref rid="B30" ref-type="bibr">30</xref>).</p></sec><sec id="s6_2"><label>6.2</label><title>Rationale for DDR-ICB combination therapy</title><p>The combination of DDR inhibitors with immune checkpoint blockers (ICBs) represents a rational strategy to overcome the immunosuppressive TME in SCLC (<xref rid="B62" ref-type="bibr">62</xref>). Mechanistically, DDR inhibition amplifies genomic instability, leading to the accumulation of cytosolic DNA and activation of the cGAS-STING pathway (<xref rid="B63" ref-type="bibr">63</xref>). This enhances tumor immunogenicity through the release of DAMPs and type I interferon-responsive chemokines (e.g., CXCL10), recruiting effector T-cells into the TME (<xref rid="B63" ref-type="bibr">63</xref>). Concurrently, DDR pathway aberrations often drive compensatory upregulation of immune checkpoints like PD-L1 (<xref rid="B38" ref-type="bibr">38</xref>). Therefore, combining DDR inhibitors with ICBs creates a synergistic loop: DDRis stimulate an immune response and increase T-cell infiltration, while ICBs prevent the inactivation of these newly recruited T-cells, effectively breaking immune tolerance (<xref rid="B64" ref-type="bibr">64</xref>). This mechanistic synergy is reflected in the superior outcomes observed in DDR-IF-high tumors, as illustrated in <xref rid="f5" ref-type="fig"><bold>Figure&#160;5</bold></xref>. Targeting non-redundant immune checkpoints beyond PD-L1, such as TIGIT or VSIG4, may further enhance this strategy (<xref rid="B65" ref-type="bibr">65</xref>). Clinical trials, such as the phase II study of olaparib and durvalumab (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02484404">NCT02484404</ext-link>), provide early evidence supporting this approach (<xref rid="B66" ref-type="bibr">66</xref>).</p><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>Schematic of key DDR pathway abnormalities and their contributions to genomic instability in SCLC. <bold>(A)</bold> Homologous recombination (HR) deficiency: Mutations in BRCA1/2 (15-20% prevalence) or dysfunction of RAD51 disrupt accurate HR repair, leading to accumulation of double-strand breaks (DSBs) and genomic instability. <bold>(B)</bold> Mismatch repair (MMR) impairment: Transcriptional silencing of MLH1 results in loss of functional MMR, failure to correct base mismatches during DNA replication, and accumulation of replication errors. <bold>(C)</bold> ATM pathway disruption: ATM mutations abrogate its phosphorylation-mediated signaling, disrupting cell cycle checkpoints (e.g., G1/S block via Chk2-P21) and HR repair (via impaired BRCA1 complex function), leading to unchecked cell proliferation despite DNA damage. <bold>(D)</bold> DNA-PKcs/KU70 deficiency: Impaired non-homologous end joining (NHEJ) increases reliance on error-prone repair mechanisms, further driving genomic instability. <bold>(E)</bold> PARP1 overactivation: Dysregulated PARP1 activity disrupts DNA damage signaling and repair coordination, while EML4-ALK rearrangement enhances DDR pathway abnormalities. Collectively, these DDR defects promote genetic mutation transmission and tumor progression, underscoring the rationale for integrating HRD and TMB (surrogates of genomic instability) into the DDR-IF score to identify tumors susceptible to PARP-ICB combination therapy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-15-1680921-g005.jpg"><alt-text content-type="machine-generated">Diagram depicting BRCA1 and BRCA2 pathways and the impact of their mutations. The top row contrasts normal homologous recombination repair with deficient repair due to BRCA2 mutations, showing the accumulation of double-strand breaks and transcriptional silencing. The middle row illustrates repair complex activity and signal disruption. The bottom row highlights error-prone repair mechanisms leading to genomic instability and impaired DNA damage response, promoting tumor progression. Key terms include MMR, ATM, RAD51, and P21.</alt-text></graphic></fig></sec><sec id="s6_3"><label>6.3</label><title>The DDR-IF score: construction, validation, and translational context</title><p>To translate the compelling biological rationale for DDR-ICB synergy into a clinically actionable tool, we developed the DDR-IF score. As detailed in the Methods section, this composite biomarker was derived from an integrated analysis of 82 treatment-na&#239;ve SCLC single-cell transcriptomes and a systematic review of six PARP-ICB phase II trials (<xref rid="B67" ref-type="bibr">67</xref>). An elastic-net regression model defined the optimal combination as: DDR-IF = 0.4&#183;HRD + 0.35&#183;log~10~(TMB + 1) + 0.25&#183;STING activation score. A cut-off of &#8805;0.65 was established to define the DDR-IF-high status.</p><p>In the independent MSK-IMPACT validation cohort (n=152), the DDR-IF score successfully stratified patients, with DDR-IF-high status being associated with significantly improved progression-free survival on PARP-ICB regimens (HR 0.45, 95% CI 0.22-0.91). However, we explicitly acknowledge several limitations. The derivation from a limited, retrospective cohort of 82 tumors poses a substantial risk of overfitting, despite employing regularized regression. Furthermore, the pooled ORR analysis from six separate trials introduces potential heterogeneity from variations in specific PARP inhibitors and ICBs used, prior lines of therapy, and patient baseline characteristics, which may confound the observed effect size. The promising performance metrics (e.g., AUROC = 0.81) must therefore be interpreted with caution, as they may not fully generalize to broader populations and could represent an optimistic estimate. Therefore, we unequivocally state that the DDR-IF score is currently an exploratory research tool and is not yet ready for routine clinical deployment. Its definitive predictive utility must be established in prospective, multi-center, biomarker-stratified clinical trials.</p></sec></sec><sec id="s7"><label>7</label><title>Clinical translation of DDR-IF</title><p>The prospective clinical application of the DDR-IF score entails a defined pathway. Key operational steps include: (i) Multi-omic Profiling: Tumor samples undergo parallel assessment of genomic instability (HRD via scarHRD and TMB from WES) and immune fitness (STING pathway activity via scRNA-seq or phospho-flow) (<xref rid="B68" ref-type="bibr">68</xref>). (ii) Algorithmic Integration: The DDR-IF score is calculated using the predefined formula, with a score of &#8805;0.65 defining DDR-IF-high status (<xref rid="B69" ref-type="bibr">69</xref>). (iii) Therapeutic Triaging: Retrospective analyses indicate that DDR-IF-high tumors (&#8805;0.65) were associated with a 42% objective response rate to PARP-ICB combinations, compared with 18% in DDR-IF-low tumors (p = 0.003) (<xref rid="B70" ref-type="bibr">70</xref>). Pending prospective validation, such combinations may be considered investigational for DDR-IF-high patients, while standard platinum-etoposide plus atezolizumab remains the backbone for DDR-IF-low disease (<xref rid="B71" ref-type="bibr">71</xref>).</p><p>This framework addresses key limitations of single-dimensional biomarkers. For instance, PD-L1 fails to predict response in STING-exhausted SCLCs, and TMB alone misses a significant proportion of DDR-IF-low tumors with defective antigen presentation. Prospective, biomarker-stratified trials will be essential to refine thresholds and determine the clinical utility of the DDR-IF score.</p></sec><sec id="s8"><label>8</label><title>Unresolved controversies and negative findings</title><p>Despite robust performance in derivation cohorts, several unresolved issues merit caution. First, ethnic variability may influence the score&#8217;s predictive power. In the MSK-IMPACT cohort, DDR-IF-high patients of Caucasian ancestry showed a less pronounced PFS benefit (HR 0.62) compared to Asian populations (HR 0.45), potentially due to a higher prevalence of STING-desert phenotypes (35% <italic toggle="yes">vs</italic>. 22%) and divergent ATM mutation spectra (<xref rid="B72" ref-type="bibr">72</xref>). Second, discordant therapeutic responses exist within DDR-IF-high subgroups; 10% of patients exhibited primary resistance, associated with TIGIT/VISTA co-expression or HLA loss of heterozygosity (<xref rid="B73" ref-type="bibr">73</xref>). Third, technical discrepancies in STING quantification emerged, with 25% discordance between mRNA-based and protein-based assays (<xref rid="B74" ref-type="bibr">74</xref>). These findings underscore the need for: (i) prospective, multi-center trials with pre-planned, ethnicity-stratified analyses (e.g., Asian <italic toggle="yes">vs</italic>. Caucasian) to establish generalizable or population-specific calibration curves and cut-off values for the DDR-IF score; (ii) augmenting DDR-IF with additional immune screens (e.g., TIGIT/VISTA) to explain primary resistance; and (iii) orthogonal STING validation (e.g., phospho-flow cytometry for p-STING) coupled with platform-specific standardization before clinical implementation.</p></sec><sec id="s9"><label>9</label><title>Discussion and conclusion</title><p>Rationale and Comparative Advantage of the DDR-IF Score.</p><p>The development of the DDR-IF score was motivated by the inherent limitations of existing, one-dimensional biomarkers in predicting response to combination therapy in ES-SCLC. Biomarkers such as SLFN11 expression and ATM mutation status, while associated with PARPi sensitivity, primarily reflect intrinsic tumor cell vulnerability and fail to capture the immune contexture essential for predicting synergy with ICBs (<xref rid="B75" ref-type="bibr">75</xref>). Similarly, while TMB and PD-L1 are valuable in NSCLC, they are insufficient as standalone biomarkers in SCLC. PD-L1 expression can be transient and is often misleading in the context of STING pathway exhaustion, and TMB does not necessarily correlate with functional antigen presentation, a common defect in DDR-deficient tumors (<xref rid="B76" ref-type="bibr">76</xref>). The DDR-IF score directly addresses these gaps by integrating measures of genomic instability (HRD, TMB) with a key immune activation pathway (STING) (<xref rid="B68" ref-type="bibr">68</xref>). Consequently, our analysis demonstrates that the DDR-IF score provides superior predictive efficacy for PARP-ICB response compared to a simple TMB-PD-L1 composite model (AUC 0.81 <italic toggle="yes">vs</italic>. 0.72) and outperforms models based solely on SLFN11 or ATM.</p><p>However, we must emphasize that the superior performance of the DDR-IF score in our derivation cohort, while promising, is derived from a limited sample size (n=82). The potential for overfitting and the cohort heterogeneity from pooling trial data necessitate that these performance metrics (e.g., AUROC = 0.81) be interpreted as exploratory. Their generalizability and true effect size must be confirmed in the planned prospective, multi-center studies.</p><p>These comparative advantages are further summarized in <xref rid="SF1" ref-type="supplementary-material"><bold>Supplementary Table S1</bold></xref>, which highlights the DDR-IF score&#8217;s superior AUROC performance and broader applicability in PARP-ICB combination therapy compared to existing single-dimensional biomarkers such as SLFN11, TMB, HRD score, and ATM status.</p></sec><sec id="s10"><label>10</label><title>Mechanistic insight: decoding the &#8220;immunologically cold&#8221; DDR-IF-High phenotype</title><p>The DDR-IF score mechanistically identifies a specific &#8220;immunologically cold&#8221; phenotype driven by cGAS-STING pathway exhaustion (<xref rid="B77" ref-type="bibr">77</xref>). This state, characterized by diminished STING protein phosphorylation and impaired production of downstream effectors like IFN-&#946; and CXCL10, is distinct from the adaptive immune dysfunction of T-cell exhaustion (<xref rid="B78" ref-type="bibr">78</xref>). It results in a profoundly interferon-desert TME with scant CD8<sup>+</sup> T cell infiltration, as evidenced by our multiplex immunohistochemistry data. This clarifies a central paradox in SCLC immunotherapy: why tumors with high genomic instability (e.g., elevated HRD/TMB) can remain refractory to ICB monotherapy-they lack the functional innate immune sensing apparatus necessary to initiate an adaptive anti-tumor response. Our framework aligns with the broader understanding that STING pathway integrity is a critical determinant of immunotherapy efficacy.</p></sec><sec id="s11"><label>11</label><title>Therapeutic implications and future directions</title><p>Beyond patient stratification for PARP-ICB, the DDR-IF framework logically informs novel therapeutic strategies (<xref rid="B79" ref-type="bibr">79</xref>). DDR-IF-high tumors, defined by STING exhaustion, represent ideal candidates for interventions aimed at reversing this state (<xref rid="B79" ref-type="bibr">79</xref>). For instance, pharmacological STING agonists could be employed to directly reverse the pathway exhaustion and re-sensitize these immunologically cold tumors to checkpoint blockade (<xref rid="B80" ref-type="bibr">80</xref>). For instance, pharmacological STING agonists (<xref rid="B81" ref-type="bibr">81</xref>) or novel delivery systems (<xref rid="B82" ref-type="bibr">82</xref>) could be employed to directly reverse this pathway exhaustion and re-sensitize these immunologically cold tumors to checkpoint blockade, a strategy particularly suited for DDR-IF-high patients. Furthermore, our data on DDR-driven upregulation of non-redundant checkpoints like TIGIT and VSIG4 suggest that rational combinations of a DDR inhibitor (e.g., ATRi) with dual TIGIT/VSIG4 blockade represent a highly promising strategy for DDR-IF-high patients, potentially superior to PARP-ICB alone. This expands the translational utility of our score from a predictive biomarker to a potential guide for designing next-generation rational combination therapies.</p></sec><sec id="s12"><label>12</label><title>Limitations and path to clinical translation</title><p>We must underscore the exploratory nature of the current DDR-IF score. Its derivation from a limited, retrospective cohort (n=82) inherently carries a risk of overfitting, despite the use of regularized regression. Furthermore, ethnic variability warrants careful attention. Our preliminary analysis revealed significant differences in STING activation scores between populations of Asian and Caucasian ancestry, likely influenced by TMEM173 polymorphisms. Therefore, future prospective trials must include pre-planned, ethnicity-stratified analyses to establish the generalizability and, if necessary, population-specific calibration of the DDR-IF score. Technical standardization of STING quantification across platforms is another critical prerequisite for clinical implementation.</p></sec><sec sec-type="conclusions" id="s13"><label>13</label><title>Conclusion</title><p>In summary, the DDR-IF score integrates genomic instability and immune contexture to identify ES-SCLC tumors most susceptible to PARP-ICB synergy. While it represents a promising and mechanistically grounded precision oncology framework, its current limitations-including derivation from a small retrospective cohort, unresolved ethnic variability, and technical challenges in STING quantification-must be overcome. Its clinical translation therefore mandates rigorous prospective validation in large, multi-center, biomarker-stratified cohorts. Confirming its utility in this setting is the essential next step to addressing the profound unmet need in ES-SCLC.</p></sec></body><back><ack><title>Acknowledgments</title><p>We sincerely acknowledge the invaluable support of all staff in the Department of Oncology and Department of Surgery at the First Affiliated Hospital of Jinzhou Medical University. We are also grateful to all individuals and organizations that contributed to the success of this research.</p></ack><fn-group><fn id="n1" fn-type="edited-by"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/640604" ext-link-type="uri">Fabrizio Carta</ext-link>, University of Florence, Italy</p></fn><fn id="n2" fn-type="reviewed-by"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1174204" ext-link-type="uri">Yuba Raj Pokharel</ext-link>, South Asian University, India</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1659580" ext-link-type="uri">Pranabananda Dutta</ext-link>, Charles R. Drew University of Medicine and Science, United States</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2431852" ext-link-type="uri">Caterina De Rosa</ext-link>, University of Campania Luigi Vanvitelli, Italy</p></fn></fn-group><fn-group><fn fn-type="abbr" id="abbrev1"><p><bold>Abbreviations:</bold> SCLC, Small Cell Lung Cancer; DDR, DNA Damage Repair; ORR, Overall Response Rate; HR, Homologous Recombination; BER, Base Excision Repair; DSBs, Double-Strand Breaks; SSBs, Single-Strand Breaks; ATM, Ataxia Telangiectasia Mutated; ATR, Ataxia Telangiectasia and Rad3-Related; TME, Tumor Microenvironment; DAMP, Damage Associated Molecular Pattern; TILs, Tumor Infiltrating Lymphocytes; HRD, Homologous Recombination Deficiency; TMB, Tumor mutation burden; CUT&amp;RUN, Cleavage Under Targets and Release Using Nuclease.</p></fn></fn-group><sec sec-type="author-contributions" id="s14"><title>Author contributions</title><p>YZ: Writing &#8211; review &amp; editing. XC: Writing &#8211; original draft. DW: Writing &#8211; original draft. XZ: Formal Analysis, Writing &#8211; review &amp; editing. YW: Investigation, Writing &#8211; review &amp; editing. GZ: Data curation, Resources, Writing &#8211; review &amp; editing. XL: Investigation, Project administration, Supervision, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s16"><title>Conflict of interest</title><p>The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s17"><title>Generative AI statement</title><p>The author(s) declare that Generative AI was not used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s18"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s19"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2025.1680921/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fonc.2025.1680921/full#supplementary-material</ext-link></p><supplementary-material id="SF1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary methods</label><caption><p>Single-cell GSVA parameters. STING pathway activation was quantified with GSVA (v1.46.0) using the curated gene set HALLMARK_INTERFERON_ALPHA_RESPONSE plus 12 manually curated STING core genes (TBK1, IRF3, IFNB1, CCL5, CXCL10 etc.). Parameters: method=&#8220;gsva&#8221;, kcdf=&#8220;Gaussian&#8221;, mx.diff=TRUE, abs.ranking=FALSE. All TPM matrices were log2-transformed (pseudocount = 1) prior to GSVA. QC thresholds: &#8805;500 genes/cell, mitochondrial fraction &#8804;15%. Scripts are located in the/scr folder of the GitHub repository. STING activation was quantified via GSVA (scRNA-seq) rather than phospho-flow/NanoString due to sample availability. Cross-platform validation in 20 matched samples revealed moderate correlation (r = 0.67, p = 0.01), suggesting cut-offs may require adjustment for non-transcriptomic assays.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table1.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SF2" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Figure&#160;1</label><caption><p>PRISMA-2020 flow diagram of literature search and trial selection for DDR-IF score derivation. A systematic search was conducted across PubMed, Embase, Cochrane Library, and ClinicalTrials.gov (inception to April 2024) using keywords and MeSH terms related to small cell lung cancer (SCLC), PARP inhibitors, immunotherapy, and clinical trials. Of 428 total identified records, 112 duplicates were removed, leaving 316 for title/abstract screening. After excluding non-phase II trials, non-extensive-stage (ES)-SCLC studies, non-PARP-ICB combination therapies, and studies lacking objective response rate (ORR) data, 28 records proceeded to full-text review.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image1.jpeg" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Sun</surname><given-names>JM</given-names></name><name name-style="western"><surname>Park</surname><given-names>WY</given-names></name><etal/></person-group>. 
<article-title>DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC</article-title>. <source>J Thorac Oncol</source>. (<year>2019</year>) <volume>14</volume>:<page-range>1640&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jtho.2019.05.014</pub-id>, PMID: 
<pub-id pub-id-type="pmid">31125737</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name></person-group>. 
<article-title>Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy</article-title>. <source>Cancer Treat Rev</source>. (<year>2023</year>) <volume>120</volume>:<fpage>102606</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102606</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37579532</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Gu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. 
<article-title>Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape</article-title>. <source>Mol Cancer</source>. (<year>2021</year>) <volume>20</volume>:<fpage>130</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12943-021-01432-5</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34620176</pub-id><pub-id pub-id-type="pmcid">PMC8496044</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name><name name-style="western"><surname>Barayan</surname><given-names>R</given-names></name><name name-style="western"><surname>Louie</surname><given-names>AV</given-names></name><name name-style="western"><surname>Lok</surname><given-names>BH</given-names></name></person-group>. 
<article-title>Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review</article-title>. <source>Semin Cancer Biol</source>. (<year>2022</year>) <volume>86</volume>:<page-range>521&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.semcancer.2022.07.008</pub-id>, PMID: 
<pub-id pub-id-type="pmid">35917883</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>P</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group>. 
<article-title>DDR pathway alteration, tumor mutation burden, and cisplatin sensitivity in small cell lung cancer: difference detected by whole exome and targeted gene sequencing</article-title>. <source>J Thorac Oncol</source>. (<year>2019</year>) <volume>14</volume>:<page-range>e276&#8211;e9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jtho.2019.08.2509</pub-id>, PMID: 
<pub-id pub-id-type="pmid">31757380</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owonikoko</surname><given-names>TK</given-names></name><name name-style="western"><surname>Dahlberg</surname><given-names>SE</given-names></name><name name-style="western"><surname>Sica</surname><given-names>GL</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>LI</given-names></name><name name-style="western"><surname>Wade</surname><given-names>JL</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Srkalovic</surname><given-names>G</given-names></name><etal/></person-group>. 
<article-title>Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study</article-title>. <source>J Clin Oncol</source>. (<year>2019</year>) <volume>37</volume>:<page-range>222&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.18.00264</pub-id>, PMID: 
<pub-id pub-id-type="pmid">30523756</pub-id><pub-id pub-id-type="pmcid">PMC6338394</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group>. 
<article-title>Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy</article-title>. <source>Cancer Cell</source>. (<year>2025</year>) <volume>43</volume>:<fpage>503</fpage>&#8211;<lpage>18.e10</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2025.02.014</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40068600</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Meng</surname><given-names>H</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group>. 
<article-title>Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors</article-title>. <source>BioMed Pharmacother</source>. (<year>2024</year>) <volume>175</volume>:<fpage>116733</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.116733</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38754267</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rimner</surname><given-names>A</given-names></name><name name-style="western"><surname>Lai</surname><given-names>WV</given-names></name><name name-style="western"><surname>Califano</surname><given-names>R</given-names></name><name name-style="western"><surname>Jabbour</surname><given-names>SK</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>CM</given-names></name><name name-style="western"><surname>Faivre-Finn</surname><given-names>C</given-names></name><etal/></person-group>. 
<article-title>Rationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung cancer</article-title>. <source>Clin Lung Cancer</source>. (<year>2022</year>) <volume>23</volume>:<page-range>e325&#8211;e9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cllc.2022.04.005</pub-id>, PMID: 
<pub-id pub-id-type="pmid">35613997</pub-id><pub-id pub-id-type="pmcid">PMC10905605</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mouw</surname><given-names>KW</given-names></name></person-group>. 
<article-title>DNA repair deficiency and the immune microenvironment: A pathways perspective</article-title>. <source>DNA Repair (Amst)</source>. (<year>2024</year>) <volume>133</volume>:<fpage>103594</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.dnarep.2023.103594</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37980867</pub-id><pub-id pub-id-type="pmcid">PMC10841828</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joris</surname><given-names>S</given-names></name><name name-style="western"><surname>Denys</surname><given-names>H</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>J</given-names></name><name name-style="western"><surname>Rasschaert</surname><given-names>M</given-names></name><name name-style="western"><surname>T&#8217;Kint de Roodenbeke</surname><given-names>D</given-names></name><name name-style="western"><surname>Duhoux</surname><given-names>FP</given-names></name><etal/></person-group>. 
<article-title>Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study</article-title>. <source>ESMO Open</source>. (<year>2023</year>) <volume>8</volume>:<fpage>102041</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.esmoop.2023.102041</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37852034</pub-id><pub-id pub-id-type="pmcid">PMC10774963</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>M</given-names></name><name name-style="western"><surname>Gai</surname><given-names>J</given-names></name><name name-style="western"><surname>McPhaul</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group>. 
<article-title>Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer</article-title>. <source>Exp Hematol Oncol</source>. (<year>2025</year>) <volume>14</volume>:<fpage>86</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40164-025-00673-0</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40533854</pub-id><pub-id pub-id-type="pmcid">PMC12178057</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leuzzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Vasciaveo</surname><given-names>A</given-names></name><name name-style="western"><surname>Taglialatela</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Firestone</surname><given-names>TM</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>AR</given-names></name><etal/></person-group>. 
<article-title>SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion</article-title>. <source>Cell</source>. (<year>2024</year>) <volume>187</volume>:<fpage>861</fpage>&#8211;<lpage>81.e32</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2024.01.008</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38301646</pub-id><pub-id pub-id-type="pmcid">PMC10980358</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Elenbaas</surname><given-names>B</given-names></name><name name-style="western"><surname>Murugesan</surname><given-names>K</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K</given-names></name><name name-style="western"><surname>Montesion</surname><given-names>M</given-names></name><name name-style="western"><surname>Gounaris</surname><given-names>I</given-names></name><etal/></person-group>. 
<article-title>Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays</article-title>. <source>NPJ Precis Oncol</source>. (<year>2023</year>) <volume>7</volume>:<fpage>103</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41698-023-00442-4</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37821580</pub-id><pub-id pub-id-type="pmcid">PMC10567713</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies</article-title>. <source>Cell</source>. (<year>2024</year>) <volume>187</volume>:<fpage>184</fpage>&#8211;<lpage>203.e28</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2023.12.004</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38181741</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collet</surname><given-names>L</given-names></name><name name-style="western"><surname>Hanvic</surname><given-names>B</given-names></name><name name-style="western"><surname>Turinetto</surname><given-names>M</given-names></name><name name-style="western"><surname>Treilleux</surname><given-names>I</given-names></name><name name-style="western"><surname>Chopin</surname><given-names>N</given-names></name><name name-style="western"><surname>Le Saux</surname><given-names>O</given-names></name><etal/></person-group>. 
<article-title>BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1354427</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2024.1354427</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38544832</pub-id><pub-id pub-id-type="pmcid">PMC10965616</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naqvi</surname><given-names>SAA</given-names></name><name name-style="western"><surname>Riaz</surname><given-names>IB</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Imran</surname><given-names>M</given-names></name><name name-style="western"><surname>Khakwani</surname><given-names>KZR</given-names></name><etal/></person-group>. 
<article-title>Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: A living interactive systematic review and meta-analysis</article-title>. <source>Eur Urol</source>. (<year>2025</year>) <volume>87</volume>:<page-range>626&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.eururo.2024.12.007</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39848867</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sankar</surname><given-names>K</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>J</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>EB</given-names></name><name name-style="western"><surname>Godden</surname><given-names>J</given-names></name><name name-style="western"><surname>Williams</surname><given-names>E</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>MA</given-names></name><etal/></person-group>. 
<article-title>DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer</article-title>. <source>Lung Cancer</source>. (<year>2025</year>) <volume>201</volume>:<fpage>108444</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.lungcan.2025.108444</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39961190</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Du</surname><given-names>H</given-names></name><etal/></person-group>. 
<article-title>Synthetic lethal co-mutations in DNA damage response pathways predict response to immunotherapy in pan-cancer</article-title>. <source>JCO Precis Oncol</source>. (<year>2025</year>) <volume>9</volume>:<fpage>e2500035</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1200/PO-25-00035</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40440584</pub-id><pub-id pub-id-type="pmcid">PMC12144546</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name></person-group>. 
<article-title>Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types</article-title>. <source>Cancer Biol Med</source>. (<year>2021</year>) <volume>18</volume>:<page-range>1080&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2020.0351</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33960179</pub-id><pub-id pub-id-type="pmcid">PMC8610155</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S</given-names></name><name name-style="western"><surname>Suh</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><etal/></person-group>. 
<article-title>Comparison of the predictive power of a combination versus individual biomarker testing in non-small cell lung cancer patients treated with immune checkpoint inhibitors</article-title>. <source>Cancer Res Treat</source>. (<year>2022</year>) <volume>54</volume>:<page-range>424&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4143/crt.2021.583</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34237208</pub-id><pub-id pub-id-type="pmcid">PMC9016300</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshi</surname><given-names>M</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name><name name-style="western"><surname>Asaoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>A</given-names></name><etal/></person-group>. 
<article-title>Development of a novel BRCAness score that predicts response to PARP inhibitors</article-title>. <source>biomark Res</source>. (<year>2022</year>) <volume>10</volume>:<fpage>80</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40364-022-00427-8</pub-id>, PMID: 
<pub-id pub-id-type="pmid">36371386</pub-id><pub-id pub-id-type="pmcid">PMC9652967</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>. 
<article-title>Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors</article-title>. <source>Cell</source>. (<year>2024</year>) <volume>187</volume>:<fpage>4905</fpage>&#8211;<lpage>25.e24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2024.06.013</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38971151</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Yue</surname><given-names>L</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Wan</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><etal/></person-group>. 
<article-title>Novel cyano-artemisinin dimer ZQJ29 targets PARP1 to induce ferroptosis in pancreatic cancer treatment</article-title>. <source>Adv Sci (Weinh)</source>. (<year>2025</year>) <volume>12</volume>:<fpage>e01935</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/advs.202501935</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40387570</pub-id><pub-id pub-id-type="pmcid">PMC12362764</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group>. 
<article-title>Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader</article-title>. <source>Cell Death Dis</source>. (<year>2024</year>) <volume>15</volume>:<fpage>898</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41419-024-07277-2</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39695097</pub-id><pub-id pub-id-type="pmcid">PMC11655542</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iglesias</surname><given-names>P</given-names></name><name name-style="western"><surname>Seoane</surname><given-names>M</given-names></name><name name-style="western"><surname>Gol&#225;n</surname><given-names>I</given-names></name><name name-style="western"><surname>Castro-Piedras</surname><given-names>I</given-names></name><name name-style="western"><surname>Fraga</surname><given-names>M</given-names></name><name name-style="western"><surname>Arce</surname><given-names>VM</given-names></name><etal/></person-group>. 
<article-title>PARP1 deficiency reduces tumour growth by decreasing E2F1 hyperactivation: A novel mechanism in the treatment of cancer</article-title>. <source>Cancers (Basel)</source>. (<year>2020</year>) <volume>12</volume>:<fpage>2907</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers12102907</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33050515</pub-id><pub-id pub-id-type="pmcid">PMC7599842</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuzaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>A</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>M</given-names></name></person-group>. 
<article-title>Human AAA+ ATPase FIGNL1 suppresses RAD51-mediated ultra-fine bridge formation</article-title>. <source>Nucleic Acids Res</source>. (<year>2024</year>) <volume>52</volume>:<page-range>5774&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkae263</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38597669</pub-id><pub-id pub-id-type="pmcid">PMC11162793</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>T</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>E</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JT</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuentas</surname><given-names>ERP</given-names></name><etal/></person-group>. 
<article-title>Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation</article-title>. <source>Clin Cancer Res</source>. (<year>2022</year>) <volume>28</volume>:<page-range>3669&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1278</pub-id>, PMID: 
<pub-id pub-id-type="pmid">35736816</pub-id><pub-id pub-id-type="pmcid">PMC9444971</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Barge</surname><given-names>A</given-names></name><name name-style="western"><surname>Parris</surname><given-names>CN</given-names></name></person-group>. 
<article-title>Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms</article-title>. <source>Oncogene</source>. (<year>2025</year>) <volume>44</volume>:<fpage>193</fpage>&#8211;<lpage>207</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41388-024-03227-6</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39572842</pub-id><pub-id pub-id-type="pmcid">PMC11746151</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deligianni</surname><given-names>E</given-names></name><name name-style="western"><surname>Papanikolaou</surname><given-names>C</given-names></name><name name-style="western"><surname>Terpos</surname><given-names>E</given-names></name><name name-style="western"><surname>Souliotis</surname><given-names>VL</given-names></name></person-group>. 
<article-title>Elucidating DNA damage-dependent immune system activation</article-title>. <source>Int J Mol Sci</source>. (<year>2025</year>) <volume>26</volume>:<fpage>5849</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms26125849</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40565309</pub-id><pub-id pub-id-type="pmcid">PMC12192923</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name></person-group>. 
<article-title>Helicobacter pylori and gastric cancer: mechanisms and new perspectives</article-title>. <source>J Hematol Oncol</source>. (<year>2025</year>) <volume>18</volume>:<fpage>10</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13045-024-01654-2</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39849657</pub-id><pub-id pub-id-type="pmcid">PMC11756206</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>He</surname><given-names>YY</given-names></name><name name-style="western"><surname>Yao</surname><given-names>WX</given-names></name><name name-style="western"><surname>Jin</surname><given-names>DD</given-names></name><name name-style="western"><surname>Luo</surname><given-names>HN</given-names></name><name name-style="western"><surname>Li</surname><given-names>MY</given-names></name><etal/></person-group>. 
<article-title>Primary cilia prevent activation of the cGAS-STING pathway during mouse decidualization</article-title>. <source>Commun Biol</source>. (<year>2025</year>) <volume>8</volume>:<fpage>607</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s42003-025-08030-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40229503</pub-id><pub-id pub-id-type="pmcid">PMC11997147</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name></person-group>. 
<article-title>Significance of the cGAS-STING pathway in health and disease</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<fpage>13316</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms241713316</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37686127</pub-id><pub-id pub-id-type="pmcid">PMC10487967</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M</given-names></name></person-group>. 
<article-title>Cold and hot tumors: from molecular mechanisms to targeted therapy</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2024</year>) <volume>9</volume>:<fpage>274</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41392-024-01979-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39420203</pub-id><pub-id pub-id-type="pmcid">PMC11491057</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miglietta</surname><given-names>G</given-names></name><name name-style="western"><surname>Russo</surname><given-names>M</given-names></name><name name-style="western"><surname>Capranico</surname><given-names>G</given-names></name><name name-style="western"><surname>Marinello</surname><given-names>J</given-names></name></person-group>. 
<article-title>Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy</article-title>? <source>Br J Cancer</source>. (<year>2024</year>) <volume>131</volume>:<page-range>1567&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41416-024-02821-5</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39215193</pub-id><pub-id pub-id-type="pmcid">PMC11555062</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Concannon</surname><given-names>K</given-names></name><name name-style="western"><surname>Morris</surname><given-names>BB</given-names></name><name name-style="western"><surname>Gay</surname><given-names>CM</given-names></name><name name-style="western"><surname>Byers</surname><given-names>LA</given-names></name></person-group>. 
<article-title>Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control</article-title>. <source>Mol Cell</source>. (<year>2023</year>) <volume>83</volume>:<page-range>660&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molcel.2022.12.031</pub-id>, PMID: 
<pub-id pub-id-type="pmid">36669489</pub-id><pub-id pub-id-type="pmcid">PMC9992136</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabanon</surname><given-names>RM</given-names></name><name name-style="western"><surname>Danlos</surname><given-names>FX</given-names></name><name name-style="western"><surname>Ouali</surname><given-names>K</given-names></name><name name-style="western"><surname>Postel-Vinay</surname><given-names>S</given-names></name></person-group>. 
<article-title>Genome instability and crosstalk with the immune response</article-title>. <source>Genome Med</source>. (<year>2025</year>) <volume>17</volume>:<fpage>139</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13073-025-01509-6</pub-id>, PMID: 
<pub-id pub-id-type="pmid">41188872</pub-id><pub-id pub-id-type="pmcid">PMC12587660</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>K</given-names></name><name name-style="western"><surname>Das</surname><given-names>T</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>AM</given-names></name></person-group>. 
<article-title>Pancancer analysis of DNA damage repair gene mutations and their impact on immune regulatory gene expression</article-title>. <source>Sci Rep</source>. (<year>2025</year>) <volume>15</volume>:<fpage>15667</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-025-99965-y</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40325163</pub-id><pub-id pub-id-type="pmcid">PMC12052996</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>. 
<article-title>Inhibition of ATM enhances the immunogenicity of triple-negative breast cancer by promoting MHC-I expression</article-title>. <source>Cell Death Dis</source>. (<year>2025</year>) <volume>16</volume>:<fpage>624</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41419-025-07944-y</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40825766</pub-id><pub-id pub-id-type="pmcid">PMC12361503</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. 
<article-title>ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer</article-title>. <source>J Immunother Cancer</source>. (<year>2021</year>) <volume>9</volume>:<elocation-id>e001758</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2020-001758</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34301812</pub-id><pub-id pub-id-type="pmcid">PMC8296819</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group>. 
<article-title>Ferroptosis: CD8(+)T cells&#8217; blade to destroy tumor cells or poison for self-destruction</article-title>. <source>Cell Death Discov</source>. (<year>2025</year>) <volume>11</volume>:<fpage>128</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41420-025-02415-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40169575</pub-id><pub-id pub-id-type="pmcid">PMC11962101</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JW</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>YC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HM</given-names></name></person-group>. 
<article-title>CD155 as an emerging target in tumor immunotherapy</article-title>. <source>Int Immunopharmacol</source>. (<year>2024</year>) <volume>131</volume>:<fpage>111896</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.intimp.2024.111896</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38518596</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>DNA damage and activation of cGAS/STING pathway induce tumor microenvironment remodeling</article-title>. <source>Front Cell Dev Biol</source>. (<year>2021</year>) <volume>9</volume>:<elocation-id>828657</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcell.2021.828657</pub-id>, PMID: 
<pub-id pub-id-type="pmid">35265630</pub-id><pub-id pub-id-type="pmcid">PMC8900217</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>BS</given-names></name></person-group>. 
<article-title>RAD51-mediated homologous recombination is a pro-tumour driver pathway</article-title>. <source>Oncogene</source>. (<year>2025</year>) <volume>44</volume>:<page-range>4006&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41388-025-03583-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40993217</pub-id><pub-id pub-id-type="pmcid">PMC12518138</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>T</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>BL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Corte</surname><given-names>CMD</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>J</given-names></name><etal/></person-group>. 
<article-title>Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer</article-title>. <source>Cancer Discov</source>. (<year>2019</year>) <volume>9</volume>:<page-range>646&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1020</pub-id>, PMID: 
<pub-id pub-id-type="pmid">30777870</pub-id><pub-id pub-id-type="pmcid">PMC6563834</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Si</surname><given-names>F</given-names></name><name name-style="western"><surname>Bagley</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy</article-title>. <source>J Immunother Cancer</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>e005020</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2022-005020</pub-id>, PMID: 
<pub-id pub-id-type="pmid">36192086</pub-id><pub-id pub-id-type="pmcid">PMC9535198</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gou</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group>. 
<article-title>Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications</article-title>. <source>Front Immunol</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>1592837</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2025.1592837</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40370433</pub-id><pub-id pub-id-type="pmcid">PMC12075234</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Crosstalk between cancer-associated fibroblasts and non-neuroendocrine tumor cells in small cell lung cancer involves in glycolysis and antigen-presenting features</article-title>. <source>Mol Med</source>. (<year>2024</year>) <volume>30</volume>:<fpage>274</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s10020-024-01051-y</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39722014</pub-id><pub-id pub-id-type="pmcid">PMC11669202</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group>. 
<article-title>Lactylation as a cross-regulatory node in tumor metabolism and epigenetics: insights and therapeutic implications</article-title>. <source>Front Immunol</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>1675480</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2025.1675480</pub-id>, PMID: 
<pub-id pub-id-type="pmid">41080594</pub-id><pub-id pub-id-type="pmcid">PMC12507567</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Chai</surname><given-names>P</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Lactate and lactylation in cancer</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2025</year>) <volume>10</volume>:<fpage>38</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41392-024-02082-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39934144</pub-id><pub-id pub-id-type="pmcid">PMC11814237</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>M</given-names></name><name name-style="western"><surname>Agathanggelou</surname><given-names>A</given-names></name><name name-style="western"><surname>Stankovic</surname><given-names>T</given-names></name></person-group>. 
<article-title>DNA damage response defects in hematologic Malignancies: mechanistic insights and therapeutic strategies</article-title>. <source>Blood</source>. (<year>2024</year>) <volume>143</volume>:<page-range>2123&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood.2023019963</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38457665</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Mou</surname><given-names>W</given-names></name><etal/></person-group>. 
<article-title>Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors</article-title>. <source>NPJ Biofilms Microbiomes</source>. (<year>2025</year>) <volume>11</volume>:<fpage>180</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41522-025-00819-2</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40897718</pub-id><pub-id pub-id-type="pmcid">PMC12405452</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kciuk</surname><given-names>M</given-names></name><name name-style="western"><surname>Gruszka</surname><given-names>R</given-names></name><name name-style="western"><surname>Aleksandrowicz</surname><given-names>M</given-names></name><name name-style="western"><surname>&#346;liwi&#324;ska</surname><given-names>A</given-names></name><name name-style="western"><surname>Kontek</surname><given-names>R</given-names></name></person-group>. 
<article-title>ATR-CHK1 axis inhibitors in gastric cancer treatment</article-title>. <source>Int J Mol Sci</source>. (<year>2025</year>) <volume>26</volume>:<fpage>7709</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms26167709</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40869030</pub-id><pub-id pub-id-type="pmcid">PMC12386817</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Bing</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name></person-group>. 
<article-title>Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy</article-title>. <source>Exp Hematol Oncol</source>. (<year>2025</year>) <volume>14</volume>:<fpage>37</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40164-025-00627-6</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40087690</pub-id><pub-id pub-id-type="pmcid">PMC11907956</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group>. 
<article-title>Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2025</year>) <volume>74</volume>:<fpage>134</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00262-025-03985-6</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40035834</pub-id><pub-id pub-id-type="pmcid">PMC11880484</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>SB</given-names></name><name name-style="western"><surname>Wanderley</surname><given-names>CWS</given-names></name><name name-style="western"><surname>Colli</surname><given-names>LM</given-names></name></person-group>. 
<article-title>Immune checkpoint inhibitors in tumors harboring homologous recombination deficiency: challenges in attaining efficacy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>826577</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.826577</pub-id>, PMID: 
<pub-id pub-id-type="pmid">35211121</pub-id><pub-id pub-id-type="pmcid">PMC8860897</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group>. 
<article-title>Exploring Rad51 inhibition mechanisms of B02 and IBR2 and identifying prospective drug candidates for Rad51: A computational investigation</article-title>. <source>Comput Biol Med</source>. (<year>2025</year>) <volume>191</volume>:<fpage>110105</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.compbiomed.2025.110105</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40233679</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynch</surname><given-names>RC</given-names></name><name name-style="western"><surname>Bendell</surname><given-names>JC</given-names></name><name name-style="western"><surname>Advani</surname><given-names>RH</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>GS</given-names></name><name name-style="western"><surname>Munster</surname><given-names>PN</given-names></name><name name-style="western"><surname>Patel</surname><given-names>MR</given-names></name><etal/></person-group>. 
<article-title>First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers</article-title>. <source>J Clin Oncol</source>. (<year>2021</year>) <volume>39</volume>:<page-range>3006&#8211;</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.3006</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>S</given-names></name><name name-style="western"><surname>Sen</surname><given-names>U</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>K</given-names></name><name name-style="western"><surname>Jethalia</surname><given-names>V</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>S</given-names></name><etal/></person-group>. 
<article-title>Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer</article-title>. <source>Cell Rep Med</source>. (<year>2024</year>) <volume>5</volume>:<fpage>101852</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101852</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39657664</pub-id><pub-id pub-id-type="pmcid">PMC11722101</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>T</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. 
<article-title>PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer</article-title>. <source>Oncoimmunology</source>. (<year>2025</year>) <volume>14</volume>:<fpage>2516294</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/2162402X.2025.2516294</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40497528</pub-id><pub-id pub-id-type="pmcid">PMC12160603</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer</article-title>. <source>J Transl Med</source>. (<year>2021</year>) <volume>19</volume>:<fpage>415</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12967-021-03073-0</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34620163</pub-id><pub-id pub-id-type="pmcid">PMC8499579</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otegui</surname><given-names>N</given-names></name><name name-style="western"><surname>Houry</surname><given-names>M</given-names></name><name name-style="western"><surname>Arozarena</surname><given-names>I</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>D</given-names></name><name name-style="western"><surname>Redin</surname><given-names>E</given-names></name><name name-style="western"><surname>Exposito</surname><given-names>F</given-names></name><etal/></person-group>. 
<article-title>Cancer cell-intrinsic alterations associated with an immunosuppressive tumor microenvironment and resistance to immunotherapy in lung cancer</article-title>. <source>Cancers (Basel)</source>. (<year>2023</year>) <volume>15</volume>:<fpage>3076</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers15123076</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37370686</pub-id><pub-id pub-id-type="pmcid">PMC10295869</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagar</surname><given-names>G</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>A</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>R</given-names></name><name name-style="western"><surname>Macha</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>AA</given-names></name><etal/></person-group>. 
<article-title>The future of cancer treatment: combining radiotherapy with immunotherapy</article-title>. <source>Front Mol Biosci</source>. (<year>2024</year>) <volume>11</volume>:<elocation-id>1409300</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmolb.2024.1409300</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39044839</pub-id><pub-id pub-id-type="pmcid">PMC11263218</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name></person-group>. 
<article-title>Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications</article-title>. <source>Front Oncol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>648687</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2021.648687</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34026622</pub-id><pub-id pub-id-type="pmcid">PMC8137908</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group>. 
<article-title>V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>938470</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.938470</pub-id>, PMID: 
<pub-id pub-id-type="pmid">36189222</pub-id><pub-id pub-id-type="pmcid">PMC9520664</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>A</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>S</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name></person-group>. 
<article-title>Prospects for combining immune checkpoint blockade with PARP inhibition</article-title>. <source>J Hematol Oncol</source>. (<year>2019</year>) <volume>12</volume>:<fpage>98</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13045-019-0784-8</pub-id>, PMID: 
<pub-id pub-id-type="pmid">31521196</pub-id><pub-id pub-id-type="pmcid">PMC6744711</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><etal/></person-group>. 
<article-title>IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC</article-title>. <source>Mol Cancer</source>. (<year>2025</year>) <volume>24</volume>:<fpage>187</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12943-025-02383-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40611157</pub-id><pub-id pub-id-type="pmcid">PMC12225533</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name></person-group>. 
<article-title>Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2025</year>) <volume>74</volume>:<fpage>340</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00262-025-04192-z</pub-id>, PMID: 
<pub-id pub-id-type="pmid">41094064</pub-id><pub-id pub-id-type="pmcid">PMC12528613</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group>. 
<article-title>A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1198391</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1198391</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37449209</pub-id><pub-id pub-id-type="pmcid">PMC10337997</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Vilimas</surname><given-names>R</given-names></name><name name-style="western"><surname>Trindade</surname><given-names>C</given-names></name><name name-style="western"><surname>Erwin-Cohen</surname><given-names>R</given-names></name><name name-style="western"><surname>Roper</surname><given-names>N</given-names></name><name name-style="western"><surname>Xi</surname><given-names>L</given-names></name><etal/></person-group>. 
<article-title>Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study</article-title>. <source>J Thorac Oncol</source>. (<year>2019</year>) <volume>14</volume>:<page-range>1447&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jtho.2019.04.026</pub-id>, PMID: 
<pub-id pub-id-type="pmid">31063862</pub-id><pub-id pub-id-type="pmcid">PMC6660419</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilger</surname><given-names>D</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>LW</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>SP</given-names></name></person-group>. 
<article-title>Interfaces between cellular responses to DNA damage and cancer immunotherapy</article-title>. <source>Genes Dev</source>. (<year>2021</year>) <volume>35</volume>:<page-range>602&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1101/gad.348314.121</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33888558</pub-id><pub-id pub-id-type="pmcid">PMC8091970</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Chung</surname><given-names>MS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JG</given-names></name><name name-style="western"><surname>Sim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><etal/></person-group>. 
<article-title>Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers</article-title>. <source>BMC Med</source>. (<year>2024</year>) <volume>22</volume>:<fpage>422</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12916-024-03638-y</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39334392</pub-id><pub-id pub-id-type="pmcid">PMC11438198</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>R</given-names></name><name name-style="western"><surname>Chyr</surname><given-names>J</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name></person-group>. 
<article-title>A novel integrated approach to predicting cancer immunotherapy efficacy</article-title>. <source>Oncogene</source>. (<year>2023</year>) <volume>42</volume>:<page-range>1913&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41388-023-02670-1</pub-id>, PMID: 
<pub-id pub-id-type="pmid">37100920</pub-id><pub-id pub-id-type="pmcid">PMC10244162</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kol</surname><given-names>A</given-names></name><name name-style="western"><surname>Lubbers</surname><given-names>JM</given-names></name><name name-style="western"><surname>Terwindt</surname><given-names>ALJ</given-names></name><name name-style="western"><surname>Workel</surname><given-names>HH</given-names></name><name name-style="western"><surname>Plat</surname><given-names>A</given-names></name><name name-style="western"><surname>Wisman</surname><given-names>GBA</given-names></name><etal/></person-group>. 
<article-title>Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer</article-title>. <source>Oncoimmunology</source>. (<year>2021</year>) <volume>10</volume>:<fpage>1936391</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/2162402X.2021.1936391</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34178428</pub-id><pub-id pub-id-type="pmcid">PMC8205031</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allison Stewart</surname><given-names>C</given-names></name><name name-style="western"><surname>Tong</surname><given-names>P</given-names></name><name name-style="western"><surname>Cardnell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Sen</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Gay</surname><given-names>CM</given-names></name><etal/></person-group>. 
<article-title>Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer</article-title>. <source>Oncotarget</source>. (<year>2017</year>) <volume>8</volume>:<page-range>28575&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.18632/oncotarget.15338</pub-id>, PMID: 
<pub-id pub-id-type="pmid">28212573</pub-id><pub-id pub-id-type="pmcid">PMC5438673</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>CA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ES</given-names></name></person-group>. 
<article-title>Harnessing DNA repair defects to augment immune-based therapies in triple-negative breast cancer</article-title>. <source>Front Oncol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>703802</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2021.703802</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34631532</pub-id><pub-id pub-id-type="pmcid">PMC8497895</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group>. 
<article-title>An immunotherapy guide constructed by cGAS-STING signature for breast cancer and the biofunction validation of the pivotal gene HOXC13 via <italic toggle="yes">in vitro</italic> experiments</article-title>. <source>Front Immunol</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>1586877</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2025.1586877</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40861477</pub-id><pub-id pub-id-type="pmcid">PMC12370726</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><etal/></person-group>. 
<article-title>Spatiotemporal regulation of STING activity by linear ubiquitination governs antiviral immunity</article-title>. <source>Adv Sci (Weinh)</source>. (<year>2025</year>) <volume>12</volume>:<fpage>e2417660</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/advs.202417660</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40536345</pub-id><pub-id pub-id-type="pmcid">PMC12302577</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Unlocking the therapeutic potential of the STING signaling pathway in anti-tumor treatment</article-title>. <source>Clin Exp Med</source>. (<year>2025</year>) <volume>25</volume>:<fpage>290</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10238-025-01838-1</pub-id>, PMID: 
<pub-id pub-id-type="pmid">40794212</pub-id><pub-id pub-id-type="pmcid">PMC12343656</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turley</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ward</surname><given-names>RW</given-names></name><name name-style="western"><surname>Huete-Carrasco</surname><given-names>J</given-names></name><name name-style="western"><surname>Mu&#241;oz-Wolf</surname><given-names>N</given-names></name><name name-style="western"><surname>Roche</surname><given-names>K</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><etal/></person-group>. 
<article-title>Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8(+) T cell-dependent anti-tumor immunity</article-title>. <source>Cell Rep Med</source>. (<year>2024</year>) <volume>5</volume>:<fpage>101560</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101560</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38729159</pub-id><pub-id pub-id-type="pmcid">PMC11148802</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><etal/></person-group>. 
<article-title>A dual-STING-activating nanosystem expands cancer immunotherapeutic temporal window</article-title>. <source>Cell Rep Med</source>. (<year>2024</year>) <volume>5</volume>:<fpage>101797</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101797</pub-id>, PMID: 
<pub-id pub-id-type="pmid">39454571</pub-id><pub-id pub-id-type="pmcid">PMC11604482</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name></person-group>. 
<article-title>RGD targeted magnetic ferrite nanoparticles enhance antitumor immunotherapeutic efficacy by activating STING signaling pathway</article-title>. <source>iScience</source>. (<year>2024</year>) <volume>27</volume>:<fpage>109062</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.isci.2024.109062</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38660408</pub-id><pub-id pub-id-type="pmcid">PMC11039334</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>